Skip to main content

Table 3 Factors associated with VSE bacteraemia

From: Case-case-control study on factors associated with vanB vancomycin-resistant and vancomycin-susceptible enterococcal bacteraemia

Factors associated with VSE bacteraemia

VSE cases (n = 116)

Controls (n = 116)

Univariable

Multivariable

OR

95% CI

p-value

OR

95% CI

p-value

Age, median (IQR), years

63.5 (51–76)

58 (44–68)

1.02

1.00-1.04

0.019

1.01

0.99-1.03

0.305

Female

44 (38)

53 (46)

0.74

0.44-1.23

0.243

   

Transfer from another hospital

21 (18)

14 (12)

1.64

0.77-3.46

0.198

   

Unit of admission

        

  Non-haematology/oncology to read Non-haematology/oncology

73 (63)

49 (42)

Reference

Reference

  Haematology/oncology

43 (37)

67 (58)

0.04

0.01-0.30

0.002

0.08

0.01-0.74

0.026

ICU admission in prior 30 days

29 (25)

13 (11)

2.60

1.25-5.39

0.010

1.71

0.52-5.58

0.373

CDS-VRE score, median (IQR)

0 (0–1)

0 (0–1.6)

0.89

0.66-1.20

0.446

   

Clostridium difficile toxin positive

2 (2)

1 (1)

2.00

0.18-22.06

0.571

   

Infection(s) due to pathogens other than Enterococci

43 (37)

34 (29)

1.45

0.82-2.56

0.201

   

Gastrointestinal disease

64 (55)

38 (33)

3.00

1.60-5.62

0.001

2.29

1.05-4.99

0.037

Liver disease

13 (11)

15 (13)

0.71

0.23-2.25

0.566

   

Haematological malignancy

35 (30)

63 (54)

0.15

0.06-0.39

<0.001

0.40

0.12-1.33

0.134

Bone marrow transplantation type

  Nil

105 (91)

100 (86)

 

Reference

Reference

  Autologous

2 (2)

7 (6)

0.29

0.06-1.38

0.118

   

  Allogeneic

9 (8)

9 (8)

1.00

0.38-2.66

1.000

   

Ceftriaxone days, median (IQR), days

0 (0–0.5)

0 (0)

1.10

0.99-1.24

0.088

   

Third generation cephalosporin days , median (IQR), daysa

0 (0–1)

0 (0–0.49)

1.03

0.94-1.13

0.523

   

Fluoroquinolone days, median (IQR), daysb

0 (0–1.04)

0 (0–2.42)

0.96

0.91-1.02

0.190

   

Metronidazole days, median (IQR), days

0 (0)

0 (0)

1.23

1.06-1.43

0.007

1.23

1.02-1.48

0.032

Ticarcillin-clavulanic acid days, median (IQR), days

0 (0)

0 (0)

1.02

0.93-1.11

0.711

   

Piperacillin-tazobactam days, median (IQR), days

0 (0)

0 (0)

0.89

0.79-1.00

0.054

   

Meropenem days, median (IQR), days

0 (0)

0 (0)

1.00

0.92-1.08

0.934

   

Vancomycin days, median (IQR), days

0 (0–1.25)

0 (0–2.18)

0.97

0.92-1.03

0.343

   

Neutropenia days, median (IQR), days

0

0 (0–1)

0.98

0.94-1.02

0.344

1.00

0.94-1.06

0.911

Hypoalbuminaemia days, median (IQR), days

7 (1–16)

5 (1–13.5)

1.01

0.98-1.05

0.479

1.00

0.95-1.05

0.888

Central line use

59 (51)

55 (47)

1.17

0.67-2.05

0.572

   

Mechanical ventilation

17 (15)

7 (6)

2.67

1.04-6.81

0.040

   

Urinary catheter

46 (40)

27 (23)

2.12

1.19-3.77

0.011

1.16

0.47-2.88

0.741

Parenteral nutrition

16 (14)

8 (7)

2.00

0.86-4.67

0.109

   
  1. Note:
  2. Data are number (%) of patients unless indicated otherwise.
  3. aThird generation cephalosporins include cefotaxime, ceftriaxone, and ceftazidime.
  4. bFluoroquinolones include moxifloxacin, norfloxacin and ciprofloxacin.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us